ea5163/s1709/insigna: the timing of pembrolizumab /- chemo as 1l treatment and maintenance in nsclc
Published 1 year ago • 60 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
2:53
keynote-407: pembrolizumab plus chemo improves os and pfs in nsclc
-
1:48
results of keynote-024 trial of pembrolizumab in nsclc
-
2:21
current treatment options for nsclc without driver mutations
-
3:24
novel immunotherapy agents on the horizon for lung cancer
-
3:04
keynote-024 update: pembrolizumab vs platinum-based chemotherapy in nsclc
-
4:48
keynote-091 and impower010: adjuvant chemotherapy for nsclc
-
1:42
horizon scanning in lung cancer
-
5:00
implications for pembrolizumab in nsclc
-
4:28
combining chemotherapy and immunotherapy: key trials in lung cancer
-
4:39
chemotherapy pembrolizumab: a new standard of care?
-
6:12
advances in intratumoral therapy and an update on the bdb001-102 trial
-
1:02
pembrolizumab monotherapy for nsclc: keynote-024 update
-
2:09
is the current dose of pembrolizumab approved for treating lung cancer too high?
-
3:47
pembrolizumab as treatment for oligometastatic nsclc
-
1:56
dr. levy on impact of nivolumab, pembrolizumab approvals in nsclc
-
1:33
dr. anne chiang on molecular testing in lung cancer treatment planning
-
4:13
pembrolizumab for ps2 patients with adv. nsclc: results of the peps2 trial (bmic-067)
-
2:22
moving immunotherapy to earlier lines in nsclc
-
1:23
dr. burtness on the benefit of pembrolizumab in head and neck cancer